Optimizing Antibiotic Therapy for Stenotrophomonas maltophilia Infections in Critically Ill Patients: A Pharmacokinetic/Pharmacodynamic Approach
Antibiotics · 13.06.2024 · 13 (6) · 553
DOI: 10.3390/antibiotics13060553 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antibiotics, online erschienen am 13.06.2024. Verfasst von Helena Barrasa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Intensive Care Unit, Araba University Hospital, Osakidetza Basque Health Service, 01009 Vitoria-Gasteiz, Spain. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Basque Government.
Abstract (Originalsprache)
Stenotrophomonas maltophilia is an opportunistic, multidrug-resistant non-fermentative Gram-negative bacillus, posing a significant challenge in clinical treatment due to its numerous intrinsic and acquired resistance mechanisms. This study aimed to evaluate the adequacy of antibiotics used for the treatment of S. maltophilia infections in critically ill patients using a pharmacokinetic/pharmacodynamic (PK/PD) approach. The antibiotics studied included cotrimoxazole, levofloxacin, minocycline, tigecycline, cefiderocol, and the new combination aztreonam/avibactam, which is not yet approved. By Monte Carlo simulations, the probability of target attainment (PTA), the PK/PD breakpoints, and the cumulative fraction of response (CFR) were estimated. PK parameters and MIC distributions were sourced from the literature, the European Committee on Antimicrobial Susceptibility Testing (EUCAST), and the SENTRY Antimicrobial Surveillance Program collection. Cefiderocol 2 g q8h, minocycline 200 mg q12h, tigecycline 100 mg q12h, and aztreonam/avibactam 1500/500 mg q6h were the best options to treat empirically infections due to S. maltophilia. Cotrimoxazole provided a higher probability of treatment success for the U.S. isolates than for European isolates. For all antibiotics, discrepancies between the PK/PD breakpoints and the clinical breakpoints defined by EUCAST (or the ECOFF) and CLSI were detected.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Intensive Care Unit, Araba University Hospital, Osakidetza Basque Health Service, 01009 Vitoria-Gasteiz, Spain.
- Bioaraba Health Research Institute, 01009 Vitoria-Gasteiz, Spain.
- Infectious Disease Division, Araba University Hospital, Osakidetza Basque Health Service, 01009 Vitoria-Gasteiz, Spain.
- Microbiology Laboratory, Biomedical Diagnostic Service, Hospital San Pedro, 26006 Logroño, Spain.
- Pharmacokinetic, Nanotechnology and Gene Therapy Group (PharmaNanoGene), Faculty of Pharmacy, Lascaray Research Centre, University of the Basque Country UPV/EHU, 01006 Vitoria-Gasteiz, Spain.
- Microbiology Service, Araba University Hospital, Osakidetza Basque Health Service, 01009 Vitoria-Gasteiz, Spain.
ORCID-Profile: Helena Barrasa, Leire Fernández-Ciriza, Arantxa Isla, María Ángeles Solinís, Andrés Canut-Blasco, Alicia Rodríguez-Gascón
Förderung
- Basque Government
Zitieren
APA
Barrasa, H., Morán, M. A., Fernández-Ciriza, L., Isla, A., Solinís, M. Á., Canut-Blasco, A., & Rodríguez-Gascón, A. (2024). Optimizing Antibiotic Therapy for Stenotrophomonas maltophilia Infections in Critically Ill Patients: A Pharmacokinetic/Pharmacodynamic Approach. Antibiotics, 13(6), 553. https://doi.org/10.3390/antibiotics13060553
Vancouver
Barrasa H, Morán MA, Fernández-Ciriza L, Isla A, Solinís MÁ, Canut-Blasco A, et al. Optimizing Antibiotic Therapy for Stenotrophomonas maltophilia Infections in Critically Ill Patients: A Pharmacokinetic/Pharmacodynamic Approach. Antibiotics. 2024;13(6):553. doi:10.3390/antibiotics13060553
BibTeX
@article{Barrasa2024,
author = {Barrasa, Helena and Morán, Miguel Angel and Fernández-Ciriza, Leire and Isla, Arantxa and Solinís, María Ángeles and Canut-Blasco, Andrés and Rodríguez-Gascón, Alicia},
title = {Optimizing Antibiotic Therapy for Stenotrophomonas maltophilia Infections in Critically Ill Patients: A Pharmacokinetic/Pharmacodynamic Approach},
journal = {Antibiotics},
year = {2024},
volume = {13},
number = {6},
pages = {553},
doi = {10.3390/antibiotics13060553}
}
EUVIMED